SENSICUTAN 200IU/G+3MG/G Krém Cộng hòa Séc - Tiếng Séc - SUKL (Státní ústav pro kontrolu léčiv)

sensicutan 200iu/g+3mg/g krém

harras pharma curarina arzneimittel gmbh, mnichov array - 701 sodnÁ sŮl heparinu; 7861 levomenol - krém - 200iu/g+3mg/g - heparin, kombinace

LUCENTIS 10mg/ml Rastvor za injekciju Montenegro - Tiếng Croatia - CInMED-Institut za ljekove i medicinska sredstva Crne Gore

lucentis 10mg/ml rastvor za injekciju

"novartis pharma services ag" dio stranog druŠtva podgorica - ranibizumab - rastvor za injekciju - 10mg/ml

Lucentis 10mg/mL Serbia - Tiếng Serbia - Агенција за лекове и медицинска средства Србије (Agencija za lekove i medicins)

lucentis 10mg/ml

predstavniŠtvo novartis pharma services inc. beograd (novi beograd) - ранибизумаб - rastvor za injekciju - 10mg/ml

佐骨實注射液4毫克/100毫升 Đài Loan - Tiếng Trung - 衛生福利部食品藥物管理署 (Ministry of Health and Welfare, Food And Drug Administration)

佐骨實注射液4毫克/100毫升

瑞士商愛爾康大藥廠股份有限公司台灣分公司 新北市新店區寶中路119號4樓、5樓 (20916488) - zoledronic acid monohydrate - 注射劑 - zoledronic acid monohydrate (6400001630) (eq. to zoledronic acid anhydrous 4mg)mg - zoledronic acid - 1.與標準癌症治療併用,適用於多發性骨髓瘤及固體腫瘤併有骨骼轉移之病人。用於攝護腺癌病人之骨骼轉移時,應至少接受過一種荷爾蒙治療而仍持續惡化者。2.治療惡性腫瘤之高血鈣併發症(hcm)。

佐骨實濃縮注射液4毫克/5毫升 Đài Loan - Tiếng Trung - 衛生福利部食品藥物管理署 (Ministry of Health and Welfare, Food And Drug Administration)

佐骨實濃縮注射液4毫克/5毫升

瑞士商愛爾康大藥廠股份有限公司台灣分公司 新北市新店區寶中路119號4樓、5樓 (20916488) - zoledronic acid monohydrate - 注射劑 - zoledronic acid monohydrate (6400001630) (eq. to zoledronic acid anhydrous 4mg)mg - zoledronic acid - 1.與標準癌症治療併用,適用於多發性骨髓瘤及固體腫瘤併有骨骼轉移之病人。用於攝護腺癌病人之骨骼轉移時,應至少接受過一種荷爾蒙治療而仍持續惡化者。2.治療惡性腫瘤之高血鈣併發症(hcm)。

祈萊亞靜脈輸注用懸浮液 Đài Loan - Tiếng Trung - 衛生福利部食品藥物管理署 (Ministry of Health and Welfare, Food And Drug Administration)

祈萊亞靜脈輸注用懸浮液

台灣諾華股份有限公司 臺北市中山區民生東路3段2號8樓 (01516589) - tisagenlecleucel (ctl019 cells) - 注射劑 - tisagenlecleucel (ctl019 cells) (1000000500) 1.2 x 10^6 to 6.0 x 10^8 car-positive viable t cellsq.s. - tisagenlecleucel - 經過基因修飾的自體免疫細胞療法,適用於治療:•患有難治型、移植後復發、第二次或二次以上復發之b細胞急性淋巴性白血病(all)的25歲以下兒童和年輕成人病人。•經兩線或兩線以上全身治療後之復發性或難治性瀰漫性大b細胞淋巴瘤(dlbcl)的成人病人。•經兩線或兩線以上全身治療後之復發性或難治性濾泡性淋巴瘤(fl)成人病人。